Thimble Point Acquisition Corp I, II
Thimble Point Acquisition Corp I, II is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Thimble Point Acquisition Corp I, II.
Thimble Point Acquisition Corp I, II is a company.
Key people at Thimble Point Acquisition Corp I, II.
# Thimble Point Acquisition Corp. I & II: SPAC Entities
Thimble Point Acquisition Corp. I and II are special purpose acquisition companies (SPACs) — blank check entities formed to identify and merge with operating businesses to take them public[1][4]. These are distinct entities with different trajectories: Thimble Point Acquisition Corp. I successfully completed a business combination, while Thimble Point Acquisition Corp. II represents a later iteration that did not achieve its public listing goals.
Thimble Point I, founded in 2020 and based in New Haven, Connecticut, was designed to target high-growth technology and software companies[3]. The entity completed its mission in December 2021 when it merged with Pear Therapeutics, a prescription digital therapeutics company, generating approximately $175 million in gross proceeds[5]. Thimble Point II, incorporated in 2021, followed a similar mandate but with a withdrawn IPO on March 19, 2024, after planning to raise $200 million[1].
Thimble Point Acquisition Corp. I emerged as a SPAC vehicle in 2020, led by CEO Elon S. Boms and a team of experienced executives including Chief Strategy Officer Steven J. Benson and Chief Operating Officer Michael J. Christenson[2]. The company was underwritten by major financial institutions including Citigroup and Credit Suisse, positioning it to pursue acquisitions in the technology sector[2].
The entity's defining moment came on December 3, 2021, when Thimble Point I completed its reverse merger with Pear Therapeutics[3]. This transaction marked the successful execution of the SPAC model: identifying a private company with strong growth potential and providing it with public market access. The combined entity rebranded as Pear Therapeutics, Inc. and commenced trading on Nasdaq under ticker "PEAR" on December 6, 2021[5].
Thimble Point Acquisition Corp. II, incorporated in 2021, represented a second iteration of the same investment thesis. Led by the same management team under Elon S. Boms, it targeted similar high-growth software and technology-enabled companies disrupting established markets[1][2]. However, this entity's IPO was withdrawn on March 19, 2024, indicating that market conditions or strategic considerations prevented the completion of its public offering[1].
Thimble Point entities represent the SPAC wave that gained significant momentum in the late 2010s and early 2020s. These vehicles democratized access to public markets for growth-stage technology companies that might otherwise face lengthy traditional IPO processes. The successful merger of Thimble Point I with Pear Therapeutics exemplified how SPACs could accelerate the commercialization of emerging categories — in this case, prescription digital therapeutics, a nascent but strategically important sector at the intersection of software and healthcare[5].
However, the withdrawal of Thimble Point II's IPO in March 2024 reflects the broader contraction in SPAC activity following regulatory scrutiny and market skepticism about blank check company valuations. This shift underscores how market sentiment and regulatory environment significantly influence the viability of SPAC-based capital formation strategies.
Thimble Point Acquisition Corp. I achieved its core objective through the Pear Therapeutics merger, creating a publicly traded prescription digital therapeutics leader positioned to scale FDA-authorized treatments. The success of this transaction validated the SPAC model for technology-enabled healthcare companies.
Thimble Point Acquisition Corp. II's failed IPO reflects the challenging fundraising environment for SPACs post-2022. The withdrawal suggests that even well-structured blank check companies face headwinds when market appetite for this vehicle type diminishes. For investors and entrepreneurs, these entities illustrate both the potential and limitations of SPAC-based capital formation — effective when market conditions align, but vulnerable to broader shifts in investor sentiment and regulatory frameworks.
Key people at Thimble Point Acquisition Corp I, II.
